Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

NCT01172964 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01172964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01172964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2010
Completion date
February 11, 2015
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult anaplastic astrocytoma, adult anaplastic oligoastrocytoma, adult anaplastic oligodendroglioma, adult brain tumor, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult mixed glioma, recurrent adult brain tumor, recurrent grade iii glioma, recurrent grade iv glioma, recurrent high grade glioma